Stephen Squinto, co-founder and chief global operations officer of Cheshire’s Alexion Pharmaceuticals, will retire at the end of the year, the company announced.
Squinto co-founded Alexion in 1992 with Dr. Leonard Bell, who is chairman and CEO.
Squinto led Alexion’s development of Soliris for patients with atypical hemolytic uremic syndrome — a rare disorder that causes blood clotting in the kidneys — resulting in a second approved indication for the orphan drug in the United States, Europe and Japan.
His successor is Julie O’Neill, who will hold the title of executive vice president of global operations. She joined the company in February as senior vice president of global manufacturing operations and general manager for Ireland.
Squinto will continue to be involved with the company. Upon his retirement, he will chair a newly formed scientific advisory board that will give input on Alexion’s science and drug pipeline.
Read more
Alexion grows board, names three directors
Alexion chairman dies while traveling
